Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

Home
/
update
/
details

Life Sciences Organizations Unlock Real-World Data to Advance Precision Therapies and Diagnostics for Patients

NextEdge Admin

06 Sep 2024

2 min 6 sec

Proscia®, a global leader in AI-powered pathology solutions for precision medicine, has announced the availability of a real-world data offering on its Concentriq® platform, following a successful year-long pilot. This new offering gives life sciences organizations access to de-identified, multimodal data, including pathology images, clinical, and genomic data, from a vast repository of over 10 million whole slide images. These images, enhanced with structured data from molecular tests, pathology reports, and next-generation sequencing, enable the discovery of novel therapies and diagnostics.

“Pathology, which has been largely underutilized in drug discovery, is now a key part of precision medicine,” says Ben Freiberg, Ph.D., Principal Informatics Systems Lead at Genentech. Proscia's platform bridges this gap, offering data enriched with AI-computed features for deeper insights.

Biopharmaceutical organizations can seamlessly integrate these datasets into their studies and AI model development through Concentriq, the same platform that powers their pathology workflows from biomarker discovery to clinical trials. This enables faster precision diagnostic development and distribution to a growing network of labs and health systems, allowing patients to receive tailored treatments.

“Real-world data and AI are transforming precision medicine,” said Proscia CEO David West. “Proscia is at the forefront, helping life sciences organizations harness the power of pathology, clinical, and genomic data to advance patient care."